AB
ABT
Quarter ended Sep 30, 2023 · FY2023 Q3

Abbott Laboratories (ABT) Revenue — Quarter Ended Sep 30, 2023

Revenue for the quarter was essentially flat compared to the prior quarter, but declined relative to the same quarter last year. The sequential trend shows a slight uptick after a dip in the preceding period.

Key takeaway

Quarter ended Sep 30, 2023 · FY2023 Q3

Revenue for the quarter was essentially flat compared to the prior quarter, but declined relative to the same quarter last year. The sequential trend shows a slight uptick after a dip in the preceding period.

Financial snapshot

Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.

Quarter revenue

$10.1B

Revenue reported for this quarter.

Quarter-over-quarter

+1.7%

Change from the immediately preceding quarter.

Year-over-year

-2.6%

Change from the comparable year-ago quarter.

Trailing four quarters

$40B

Sum of the latest four reported quarters.

Quarterly revenue trend

The latest four reported quarters with year-over-year comparisons.

Period endedRevenueYear-over-year change
Dec 31, 2022$10.1B-12.0%
Mar 31, 2023$9.7B-18.1%
Jun 30, 2023$10B-11.4%
Sep 30, 2023$10.1B-2.6%

Revenue performance

Reported revenue moved higher from the immediately preceding quarter, reversing a prior decline. However, compared with the same quarter one year earlier, revenue was lower.

Quarterly comparison

Revenue increased slightly from the prior quarter, but decreased from the year-ago period. The trailing twelve-month revenue figure remained unchanged from the current quarter's level.

What to watch

The filing context does not provide specific revenue drivers; monitor future filings for underlying factors behind the year-over-year decline.